Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Xolremdi (mavorixafor)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Abbisko, X4 Pharma

Drug class:

CXCR4 antagonist

Related drugs:

CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	ibrutinib + mavorixafor Sensitive: C3 – Early Trials ibrutinib + mavorixafor Sensitive : C3	ibrutinib + mavorixafor Sensitive: C3 – Early Trials ibrutinib + mavorixafor Sensitive : C3
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	mavorixafor Sensitive: C3 – Early Trials mavorixafor Sensitive : C3	mavorixafor Sensitive: C3 – Early Trials mavorixafor Sensitive : C3
MYD88 mutation + CXCR4 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation + CXCR4 mutation	Waldenstrom Macroglobulinemia	ibrutinib + mavorixafor Sensitive: C3 – Early Trials ibrutinib + mavorixafor Sensitive : C3	ibrutinib + mavorixafor Sensitive: C3 – Early Trials ibrutinib + mavorixafor Sensitive : C3